



# **ISOQOL 32nd Annual Conference**

Final Program Oral/Poster Presentations

22-25 October 2025  
Milwaukee, Wisconsin, USA

**(1001) Refining well-being measures for Sweden's ageing population: Through a cognitive testing approach**

Marie-Louise Möllerberg, PhD, Malmö university, Malmö, Sweden

**OUTSTANDING POSTER AWARD FINALIST**

**(1002) Patient-Reported Outcome (PRO) Consortium's Chronic Heart Failure (CHF) Working Group: Collaboration on qualitative research to support qualification of a step count-based measure to evaluate physical activity in persons with CHF**

Maria Mattera, MPH, Critical Path Institute, Tucson, Arizona, United States

**OUTSTANDING POSTER AWARD FINALIST**

**(1003) Symptom Severity and Quality of Life Among Long Term Metastatic Breast Cancer Survivors**

Chloe Hery, Ph.D., The Ohio State University College of Medicine, Columbus, Ohio, United States

**NEW INVESTIGATOR POSTER AWARD FINALIST**

**(1004) Using self-reported measures to assess financial toxicity in cellular therapy patients with hematologic diseases in a US setting: A scoping review**

Sarah Reed-Thryselius, MPH, Medical College of Wisconsin, Milwaukee, Wisconsin, United States

**STUDENT POSTER AWARD FINALIST**

**(1013) Assessing HIV treatment related worries and stigma: Psychometric properties of a novel, brief patient-reported outcome measure**

Irina Kolobova, ViiV Healthcare, Durham, North Carolina, United States

**(1015) Patient-reported and transfusion-related outcomes in alpha- and beta-transfusion-dependent thalassemia: A multi-region real-world survey**

Christina Chamberlain, Agios Pharmaceuticals, Cambridge, Massachusetts, United States

**(1017) Using a Multiple-Case Study Design to Explore the Experiences of Caregivers of Children with Rare Disease: Lessons Learned from a Study in Leukocyte Adhesion Deficiency, Type 1 (LAD-I)**

Meaghan O'Connor, MTS, MPH, IQVIA, Providence, Rhode Island, United States

**(1019) Clinical Symptom Profiles for People with Multiple Sclerosis**

Deborah Miller, PhD, Mellen Center, Cleveland Clinic, Cleveland, Ohio, United States

**(1021) Idiopathic multicentric Castleman disease symptom burden study (ISBUS): Emerging findings and insights**

Philip Powell, PhD, University of Sheffield, Sheffield, United Kingdom

**(1025) Intraclass Correlation Coefficients in Multilevel Structural Validation of Intensively Collected Questionnaires: A Targeted Literature Review**

Dara O'Neill, IQVIA, Barcelona, Spain

**(1027) Mind mapping: an accessible solution for qualitative data collection and visual data summarization and dissemination**

Kirsten Glynn, MPH, LUNGEvity, Boston, Massachusetts, United States

**(1029) Incorporating Qualitative Data as Evidence into Rare Disease Clinical Development Programs: Leveraging the Rare Disease Clinical Outcome Consortium**

Asha Hareendran, PhD, University of Bedfordshire, London, United Kingdom

**(1031) Migration inconsistencies in electronic Quality of Life (QOL) instruments in clinical trials**

Lindsay Hughes, IQVIA, New York, New York, United States

**(1033) Patient-reported walking difficulty predicting the post-discharge overall function in patients with lung cancer undergoing minimally invasive surgery**

Wei Dai, Department of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan, China

**(1035) Imputing item-level missingness in PRO data using continuous-time Markov models: a simulation study**

Shizhu Li, PhD, Chongqing Medical University, Chongqing, China

**(1037) Semantic analysis of the multidimensional health locus of control**

Joel Alcantara, DC, PhD, The International Chiropractic Pediatric Association, San Jose, California, United States

**(1039) Development of a tree-based graded response model R package to test for differential item functioning in patient-reported outcome measures**

Tolulope Sajobi, PhD, University of Calgary, Calgary, Alberta, Canada

**(1041) Derivation of a preference-based value set for the Short Warwick-Edinburgh Mental Well-being Scale (SWEMWBS) to allow calculation of Mental Well-being Adjusted Life Years (MWALYs)**

David Churchman, BSc, MSc, PhD., InSpired Health Outcomes, Witney, United Kingdom

**(1043) Patient-Reported Outcome Measures for Addiction Treatment: Development of a Digital Health Platform using a Patient-Centered Approach**

Yolanda Pardo, PhD, Universitat Autònoma de Barcelona, Barcelona, Spain

**(1047) Mapping the Edmonton Symptom Assessment System-revised (ESAS-r) to the EQ-5D-5L in Patients with Cancer**

Fatima Al Sayah, PhD, University of Alberta, Edmonton, Alberta, Canada

**(1049) Barriers and Facilitators to Implementation of Breast Cancer Digital Care Companion App in Community Oncology Settings**

Amanda Higgins, MPH, Brigham and Women's Hospital, Boston, Massachusetts, United States

**(1051) The Impact of Clinical Trial Participation on Quality of Life in Families Affected by Rare Disease**

Aidan Leffler, University of Washington, Bellevue, Washington, United States

**(1053) Prognostic value of health-related quality of life for major adverse cardiovascular events in myocardial infarction patients: A systematic review of prognostic models.**

Raghad AL-Kafawin, MD, MPH, University of Leeds, Leeds, United Kingdom

**(1055) Advancing Reliable Measurement in Cognitive Aging and Decision-making Ability (ARMCADA): A pilot study on financial decision-making ability measures**

Elizabeth Dworak, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States

Thursday, 23 October

9:45 AM - 10:25 AM

Thursday Poster Session 101

Regency AB

**(1057) Patient-reported outcome measures used for differences of sex development: readability analysis and content mapping**

Manraj N. Kaur, PhD, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States

**(1059) Assessing linguistic and cultural appropriateness of patient-reported outcome measures (PROMs) for people with a migration background**

Ellen Elsmann, Amsterdam UMC, location University of Amsterdam, Epidemiology and Data Science, Amsterdam, The Netherlands, Amsterdam, Netherlands

Thursday, 23 October

1:45 PM - 3:15 PM

Concurrent Oral Sessions

**Oral Session 101: QOL in Population Health**

Regency CD

Session Chair: Fatima Al Sayah, PhD, Canada

**1:50 PM - 2:06 PM (101.1) Exploring Variability in EQ VAS scores: A Systematic Review and Meta-regression of Population Health Studies**

Ling Jie Cheng, PhD, MPH, BSN (Hons), RN, National Perinatal Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom

**NEW INVESTIGATOR ORAL PRESENTATION AWARD FINALIST**

**2:06 PM - 2:22 PM (101.2) Holistic Health in Crisis: Identifying Key Health Issues and Behaviors Across 29 Nations**

Daniel Fong, PhD, The University of Hong Kong, Hong Kong, Hong Kong

**2:22 PM - 2:38 PM (101.3) Measuring What Matters in Primary Care: Health-Related Quality of Life and Its Predictors Among Users of Public Primary Care Clinics in Singapore Using the EQ-5D-5L**

Ling Jie Cheng, PhD, MPH, BSN (Hons), RN, National Perinatal Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom

**2:38 PM - 2:54 PM (101.4) Exploring the Use of Health-Related Quality of Life Measures in Africa: A systematic scoping review**

Lucky Gift Ngwira, PhD, Health Economics and Policy Unit, Kamuzu University of Health Sciences, Blantyre, Malawi

**2:54 PM - 3:10 PM (101.5) Financial toxicity and health: Results from a U.S. nationally representative survey**

Oyiza Usman, M.D., Medical College of Wisconsin, Milwaukee, Wisconsin, United States

**Oral Session 102: Hematology**

Executive A

Session Chair: Fabio Efficace, PhD, Rome

**1:50 PM - 2:06 PM (102.1) Update of the EORTC Multiple Myeloma module (QLQ-MY20): Results from qualitative interviews with patients and healthcare professionals**

Kim Cocks, PhD, Adelphi Values Ltd, Bollington, United Kingdom

**2:06 PM - 2:22 PM (102.2) Association between patient-reported adverse events (AEs) and health-related quality of life (HRQoL) in chronic myeloid leukemia (CML) – Analysis of PRO-CTCAE and PROMIS Global Health measures**

Kelly Schoenbeck, MD, University of California San Francisco, Division of Hematology and Oncology, San Francisco, California, United States

**2:22 PM - 2:38 PM (102.3) Steroid-toxicity in newly diagnosed patients with multiple myeloma treated with a limited dexamethasone regimen; results from the NMSG REST study**

Lene Kongsgaard Nielsen, PhD MD, Quality of Life Research Center, Odense University Hospital, Odense, Denmark

**2:38 PM - 2:54 PM (102.4) Patient Reported Outcome Data for Daratumumab Treatment Readiness in Multiple Myeloma; Assessing the Feasibility**

Tine Rosenberg, Cand scient, Quality of Life Research Center, Department of Hematology, Odense University Hospital, Odense, Denmark

**2:54 PM - 3:10 PM (102.5) Qualitative research to understand the burden of disease and concept relevance of the PROMIS-Fatigue for patients with sickle cell disease**

Phoebe Wright, PharmD, MS, Agios, Seattle, Washington, United States

*ISOQOL 32nd Annual Conference | Final Program Oral /Poster Presentations*

*Presenting authors indicated. The full author listing is available on the conference mobile app under the specific session. Last updated on 6 October 2025. For the most updated version of the final program, reference the mobile app.*

Thursday, 23 October

1:45 PM - 3:15 PM

Concurrent Oral Sessions

**Oral Session 103: Physical Function Assessment**

**Executive B**

Session Chair: Aaron Kaat, PhD, United States

**1:50 PM - 2:06 PM (103.1) Linking the Physical-Performance Test to the PROMIS physical function metric: results from a prospective multicenter study**

Audrey Yuki Brinker, Center for Patient-Centered Outcomes Research (CPCOR), Department of Psychosomatic Medicine, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany

**STUDENT ORAL PRESENTATION AWARD FINALIST**

**2:06 PM - 2:22 PM (103.2) Embedded cognitive debriefing to assess content validity of physical function performance outcome measures in a multi-condition validation study**

Courtney Hurt, MSW, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States

**2:22 PM - 2:38 PM (103.3) Can patient-reported and performance-based physical function measures similarly predict mortality?**

Audrey Yuki Brinker, Center for Patient-Centered Outcomes Research (CPCOR), Department of Psychosomatic Medicine, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany

**2:38 PM - 2:54 PM (103.4) The Northwestern University Clinical Outcome Assessment Team (NUCOAT) Project: Overview of Development of Cross-Cutting Physical Function Measures for Regulatory Use in Sarcopenia and Rare Disorders**

Maja Kuharic, PhD, MSc, MPharm, Northwestern University, Chicago, Illinois, United States

**2:54 PM - 3:10 PM (103.5) Identifying patients with delayed physical function recovery after solid organ transplantation using supervised cluster analysis of longitudinal PROMIS Physical Function scores**

Jad Fadlallah, MEng, HBSoc, University Health Network, Toronto, Ontario, Canada

**Oral Session 104: PROM Development & Validation**

**Executive CD**

Session Chair: Philip Powell, PhD, United Kingdom

**1:50 PM - 2:06 PM (104.1) The caregiver experience in amyotrophic lateral sclerosis (ALS): a mixed-methods study to examine the lived experience of caring for people living with ALS and to develop a novel ALS Caregiver Impact Questionnaire (ALS-CIQ)**

William (Ben) Nowell, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States

**2:06 PM - 2:22 PM (104.2) Developing a person-centered measure for contraceptive side effects**

Amelia Mackenzie, PhD, ScM, FHI 360, Annapolis, Maryland, United States

**2:22 PM - 2:38 PM (104.3) Validation of a novel patient-reported outcome instrument assessing atopic dermatitis-associated xerosis in patients with skin of color**

Christopher Hartford, Regeneron Pharmaceutical Inc., Tarrytown, New York, United States

**2:38 PM - 2:54 PM (104.4) Psychometric properties of cognition bolt-ons for the EQ-5D-3L and EQ-5D-5L: a systematic review**

Fanni Rencz, MD, MSc, PhD, DSc, Corvinus University of Budapest, Department of Health Policy & EuroQol Research Foundation, Budapest, Hungary

**2:54 PM - 3:10 PM (104.5) Development of a Nontuberculous Mycobacterial Symptom Scale (NTM-SS): Psychometric Analysis and Proposed Scale**

Emily Henkle, PhD, MPH, OHSU-PSU School of Public Health, Portland, Oregon, United States

*ISOQOL 32nd Annual Conference | Final Program Oral /Poster Presentations*

*Presenting authors indicated. The full author listing is available on the conference mobile app under the specific session. Last updated on 6 October 2025. For the most updated version of the final program, reference the mobile app.*

Thursday, 23 October

3:20 PM - 4:00 PM

Thursday Poster Session 102

Regency AB

**(1005) Expansion of the Rare Disease Clinical Outcome Assessment (COA) Resource, a Tool to Aid in COA-derived Endpoint Selection**

Lindsey Murray, PhD, Critical Path Institute, Tucson, Arizona, United States

**OUTSTANDING POSTER AWARD FINALIST**

**(1006) Building better patient recruitment strategies: What the FDA recommends and how researchers are listening**

Amanda Roussel, Adelphi Values Patient-Centered Outcomes, Boston, Massachusetts, United States

**NEW INVESTIGATOR POSTER AWARD FINALIST**

**(1007) Comparing Linking Approaches for Patient Reported Outcomes under Non-Normal Distribution: A Monte Carlo Simulation Study**

Jiwon Kim, Postdoctoral Scholar, Northwestern University, Chicago, Illinois, United States

**STUDENT POSTER AWARD FINALIST**

**(1008) Characterizing disease-related stigma and treatment-related stigma among people with HIV: insights from BEYOND**

Irina Kolobova, ViiV Healthcare, Durham, North Carolina, United States

**OUTSTANDING POSTER AWARD FINALIST**

**(1014) Ascertainment of Minimal Clinically Important Differences in the Chronic Prostatitis Symptom Index**

Zong-Shi Qin, MD, PhD, Peking University Clinical Research Institute, Beijing, China

**(1016) Enhancing health-related quality of life for care partners of individuals with traumatic brain injury: A randomized controlled trial of the CareQOL mobile health intervention**

Noelle Carlozzi, PhD, University of Michigan, Ann Arbor, Michigan, United States

**(1018) Consumer perspectives towards patient reported measures in clinical quality registries**

Rasa Ruseckaite, PhD, Monash University, Melbourne, Australia

**(1020) Meaningful within-patient change of PROMIS-Fatigue in patients with cancer cachexia in the phase 2 ponsegromab study**

Jarjeh Fang, Pfizer, New York, New York, United States

**(1022) Lessons learned from the development and implementation of an electronic patient-reported outcomes platform (MyPRO) in a Toronto community health clinic serving racialized immigrant and refugee women**

Kirsten Wade, MPH, Syneos Health, Morrisville, North Carolina, United States

**(1024) Mediating effects of diabetes distress on glycemic level and health-related quality of life among patients with type 2 diabetes mellitus: a cross-sectional study**

Huayu Li, Department of Social Medicine of School of Public Health, and Department of Pharmacy of the First Affiliated Hospital, Zhejiang University School of Medicine, China

**(1026) Regional influences on quality of life in leukaemia patients: uncovering key predictors for personalised care.**

Sam Salek, PhD RPh FFPM/FRCP GFMD MCMS FRPS FESCP, University of Hertfordshire, Hatfield, United Kingdom

**(1028) Assessing CFA model fit criteria in data conditions resembling clinical trials: A simulation study**

Brandon Foster, PhD, Humanity, Boston, Massachusetts, United States

**(1032) Psychometric Properties of the Subcutaneous Administration Assessment Questionnaire (SQAAQ)**

Chisom Kanu, RPh, PhD, Eli Lilly and Company, Indianapolis, Indiana, United States

**(1034) Association between socio-economic status and health-related quality of life in patients with relapsed/refractory multiple myeloma treated in countries with universal healthcare system and the mediating role of financial difficulties**

Francesco Sparano, Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy

**(1036) From Data Overload to Insight: Interactive visualisation of PRO-CTCAE Data with an R Shiny Tool**

Kim Cocks, PhD, Adelphi Values, Manchester, United Kingdom

**(1038) Implementation Strategies for Electronic Patient-Reported Outcomes (ePRO)-Based Cancer Symptom Management in Chinese Primary Care Settings**

Jingyu Zhang, PhD, State Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University, Chongqing, China

**(1040) Contribution of patient-reported versus clinician-reported outcomes to core domain sets and differences in expert and patient voting patterns across these domains.**

Zachary Hopkins, MD, University of Utah Health, Salt Lake City, Utah, United States

**(1042) Cross-Cultural Adaptation and Psychometric Validation of the Danish and Norwegian Versions of the Steroid Symptom Questionnaire for Multiple Myeloma (SSQ-MM)**

Tine Rosenberg, Cand scient, Quality of Life Research Center, Department of Hematology, Odense University Hospital, Odense, Denmark, Odense, Denmark

**(1044) Validation of the Treatment-Induced Neuropathy Assessment Scale (TNAS) in Chinese Cancer Patients: a prospective cohort study**

Fan Li, Chongqing Medical University, Chongqing, China

**(1046) Needs and health-related quality of life domains relevant to people in Europe undergoing cancer treatment: A systematic review of qualitative research**

Montse Ferrer, MD, PhD, Hospital del Mar Research Institute, Barcelona, Spain

**(1048) Impact of fruits and vegetable intake on HRQoL: Results from a randomized trial comparing produce prescription delivery modes**

Corneliu Bolbocean, University of Oxford, Oxford, Arkansas, United Kingdom

**(1050) Optimizing Color Schemes for Graphs: Enhancing Accessibility and Inclusivity**

Matthew O'Brien, Adelphi Values, Boston, Massachusetts, United States

**(1052) Adaptation of Goal Attainment Scaling for Prader Willi Syndrome (PWS): Development of a Goal Inventory for Standardized Implementation**

Gunes Sevinc, Ph.D., M.Sc., B.Sc., Ardea Outcomes, Vancouver, British Columbia, Canada

**(1054) Understanding health-related quality of life and experience of care in individuals with face transplantation**

Manraj N. Kaur, PhD, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States

**(1056) Scientific best practices in electronic clinical outcome assessments: a literature review from past to present**

Lindsay Hughes, IQVIA, New York, New York, United States

**(1058) Design and Implementation of an Optimized ePRO System for Thoracic Surgery Patients (Recovery Monitor): a study protocol**

Gita Mody, MD, MPH, UNC School of Medicine, Chapel Hill, North Carolina, United States

**(1060) Characterizing Variability in Patient Global Impression of Change (PGIC) and Severity (PGIS) Measures: Towards Standardization of PRO Design to Improve Development, Comparability, Translatability, and the Patient Experience**

Tim Poepel, MS, PhD, RWS, St. Louis, Missouri, United States

**(1062) Perceived stress, coping strategies and associated factors among Colombian undergraduate health science students**

Martha Rodriguez, MSc, Universidad Santo Tomás, Bucaramanga, Colombia

**(1064) Quality of Life and Return to Duty and Combat Readiness Among Obese Active-Duty and Retired Military Personnel with Low Back Pain and other Spine Conditions: A Scoping Review**

Amy Cizik, PhD, MPH, University of Utah, Salt Lake City, Utah, United States

**(1066) An "argument-based" approach to validity applied to an endocrine therapy measure of "medication usage"**

Kyra Kapsaskis, BA, UNC - Chapel Hill, Chapel Hill, North Carolina, United States

**(1068) Quality of Life in the Early Period After Allogeneic Hematopoietic Stem Cell Transplantation: Dynamics and the Impact of GVHD**

Gabriela Lampart, Jagiellonian University Medical College, Doctoral School of Medical and Health Sciences, Krakow, Poland, Kraków, Poland

**(1070) Design and Implementation of Data Quality Controls in the EQ-DAPHNIE Study: Insights from the Pilot Phase and 15-Country Analysis**

Fatima Al Sayah, Alberta PROMs & EQ-5D Research & Support Unit (APERSU), School of Public Health, University of Alberta, Edmonton, Alberta, Canada

Thursday, 23 October

4:05 PM - 5:35 PM

Concurrent Oral Sessions

**Oral Session 106: Head Neck & Lung**

Regency CD

Session Chair: Kathleen Yost, PhD, United States

**4:10 PM - 4:26 PM (106.1) Beyond Treatment Costs: Financial Hardship, Symptom Burden, and Long-term Complications in Head and Neck Cancer Survivors**

Eden Brauer, UCLA, Los Angeles, California, United States

**4:26 PM - 4:42 PM (106.2) Network Analysis of Symptom Clusters in Head and Neck Cancers**

Xiaodan Tang, PhD, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States

**4:42 PM - 4:58 PM (106.3) Experience of symptoms related to dysarthria in patients with nasopharyngeal carcinoma during radiotherapy: A descriptive qualitative study**

Fan Li, Chongqing General Hospital, Chong Qing, China

**4:58 PM - 5:14 PM (106.4) Development and Validation of the Postoperative Recovery Assessment in Lung Cancer (PRA\_Lung): A Modular Patient-Reported Outcome Measure**

Cheng Lei, Ph.D, Sichuan Cancer Hospital and Institute, Chengdu, China

**5:14 PM - 5:30 PM (106.5) Reliability and validity tests of the ISA Lung Symptom Scale reported by patients undergoing immunotherapy for lung cancer**

Jingyu Zhang, ChongQing Medical University, Chong Qing, China

**Oral Session 107: PROMs in Clinical Practice**

Executive A

Session Chair: Norah Crossnohere, PhD, United States

**4:10 PM - 4:26 PM (107.1) Bridging the gap: A conceptual framework for integrating Patient Reported Outcome Measures throughout the process of Shared Decision Making in clinical care**

Anouk Groenewegen, MSc, Department of Child and Adolescent Psychiatry and Psychosocial Care, Amsterdam UMC, University of Amsterdam, Emma Children's Hospital, Amsterdam, Netherlands

**STUDENT ORAL PRESENTATION AWARD FINALIST**

**4:26 PM - 4:42 PM (107.2) Integrating PROMs into chronic disease management: A qualitative examination of patient and clinician views on PROM acceptability and timing**

Claudia Rutherford, PhD, University of Sydney, Sydney, New South Wales, Australia

**4:42 PM - 4:58 PM (107.3) Patient education on patient-reported outcome measure completion in clinical care settings: a scoping review**

Anouk Groenewegen, MSc, Department of Child and Adolescent Psychiatry and Psychosocial Care, Amsterdam UMC, University of Amsterdam, Emma Children's Hospital, Amsterdam, Netherlands

**4:58 PM - 5:14 PM (107.4) Evaluating patient reported outcome measures (PROM) implementation initiatives in cancer care organizations: A systematic review and recommendations for standardizing terminology**

Angela Stover, PhD, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

**5:14 PM - 5:30 PM (107.5) Developing PROM-GRIP: a reporting guideline for the integration or use of PROMs in clinical practice**

Ellen Elsmann, PhD, Department of Child and Adolescent Psychiatry and Psychosocial Care, Amsterdam UMC, Emma Children's Hospital, Amsterdam, Netherlands

**NEW INVESTIGATOR ORAL PRESENTATION AWARD FINALIST**

Thursday, 23 October

4:05 PM - 5:35 PM

Concurrent Oral Sessions

**Oral Session 108: COAs in Clinical Trials**

**Executive B**

Session Chair: Kevin Weinfurt, PhD, United States

**4:10 PM - 4:26 PM (108.1) Consensus-Based Recommendations for Designing, Analyzing, Interpreting, and Presenting Patient-Reported Outcomes in Cancer Clinical Trials**

Kate Sandberg, AbbVie Inc., North Chicago, Illinois, United States

**4:26 PM - 4:42 PM (108.2) How are digital COA endpoints defined? Some examples from current efforts in drug development**

Konstantina Skaltsa, IQVIA, Barcelona, Spain

**4:42 PM - 4:58 PM (108.3) Stakeholder perspectives on possible open-label bias of patient-reported outcome results from cancer randomized controlled trials: the IMPROVe Project**

Fabio Efficace, PhD, Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy

**4:58 PM - 5:14 PM (108.4) Perceived Burden of Completing Patient-Reported Outcome Measures: Qualitative Interviews with Oncology Clinical Trial Participants**

Ashley Geiger, PhD, Takeda Development Center Americas, Inc., Lexington, Massachusetts, United States

**5:14 PM - 5:30 PM (108.5) Meaningful tolerability endpoints to capture the dynamics of side-effect experience of cancer treatment**

Konstantina Skaltsa, PhD, IQVIA, Barcelona, Spain

**Oral Session 109: Older Adults**

**Executive CD**

Session Chair: Amy Cizik, PhD MPH, United States

**4:10 PM - 4:26 PM (109.1) A gender disaggregated growth curve analysis of mobility decline and its sociodemographic correlates among community-dwelling older Nigerians**

Ogochukwu Kelechi Onyeso, PhD, Faculty of Health Sciences, University of Lethbridge, Lethbridge, Alberta, Canada

**4:26 PM - 4:42 PM (109.2) Comparing age-specific and generic well-being scales: A systematic review and content analysis for older adults**

Marie-Louise Möllerberg, PhD, Malmö university, Malmö, Sweden

**4:42 PM - 4:58 PM (109.3) Comparative performance of the EQ-5D-5L and PROMIS-10 in the elderly: Data from the EQ-DAPHNIE project in five countries**

Fatima Al Sayah, Alberta PROMs and EQ-5D Research and Support Unit (APERSU) School of Public Health, University of Alberta, Edmonton, Alberta, Canada

**4:58 PM - 5:14 PM (109.4) A pilot study of emotion and non-cognitive measures of decision-making ability in older adults within ARMCADA**

Elizabeth M. Dworak, PhD, Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States

**5:14 PM - 5:30 PM (109.5) Fear of falling as a personality-mediated experience: older adults' adaptation and identity in a shifting embodied world**

Oluwagbohunmi Awosoga, Doctorate, University of Lethbridge, Lethbridge, Alberta, Canada

Thursday, 23 October

4:05 PM - 5:35 PM

Concurrent Oral Sessions

**Oral Session 110: Mental Health**

**Milwaukee**

Session Chair: David Churchman, PhD MSc, United Kingdom

**4:10 PM - 4:26 PM (110.1) Prioritizing the Health and Well-Being of Frontline Healthcare Professionals in Canada**

Oluwagbohunmi Awosoga, PhD, MBA, University of Lethbridge, Lethbridge, Alberta, Canada

**4:26 PM - 4:42 PM (110.2) Leveraging artificial intelligence (AI) for implementation of patient-reported outcome measures (PROMs) systems in mental health care**

Amber Bailey, MHS, Sheppard Pratt, Baltimore, Maryland, United States

**4:42 PM - 4:58 PM (110.3) Assessing ADHD in Psychiatric Care: Standardized Assessment and a Novel ADHD Assessment, Developed by Clinicians with Generative AI**

Amber Bailey, MHS, Sheppard Pratt, Baltimore, Maryland, United States

**4:58 PM - 5:14 PM (110.4) Valbenazine improves the impacts and symptoms of tardive dyskinesia: topline results from the phase 4 KINECT-PRO study**

Morgan Bron, MS, PharmD, Neurocrine Biosciences, Inc., San Diego, California, United States

**5:14 PM - 5:30 PM (110.5) Association between concerns about AI in healthcare and self-reported anxiety among cancer survivors**

Maria Rincon, PhD MPH, National Cancer Institute, Rockville, Maryland, United States

Friday, 24 October

9:35 AM - 10:15 AM

Friday Poster Session 201

Regency AB

**(1009) Can AI contribute to the development of a conceptual model of the patient experience? A feasibility assessment.**

Elizabeth Collins, PhD, Clarivate, London, United Kingdom

**NEW INVESTIGATOR POSTER AWARD FINALIST**

**(1010) Meaningful change in adult attention-deficit/hyperactivity disorder (ADHD): Using vignettes to estimate thresholds for meaningful improvement and deterioration in scores on the Adult ADHD Investigator Symptom Rating Scale (AISRS)**

Dorothee Oberdhan, PhD, Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, Maryland, United States

**OUTSTANDING POSTER AWARD FINALIST**

**(1011) Differential item functioning of the PROMIS sleep disturbance – short form 8a across levels of health literacy in a community sample of adults**

Rowida Mohamed, PhD, Pritzker School of Medicine, The University of Chicago, Chicago, Illinois, United States

**OUTSTANDING POSTER AWARD FINALIST**

**(1012) Artificial intelligence meets clinical trial design: A test case in predicting patient achievement of minimal significant difference using conditional generative adversarial networks**

Siddharth Kakked, MBBS, MPH, OPEN Health, Falmouth, Maine, United States

**STUDENT POSTER AWARD FINALIST**

**(2013) Reliability of “baseline” scores for traumatically injured patients: advantages of using the Patient-Reported Measurement Information System (PROMIS) domains**

Amy Cizik, PhD, MPH, University of Utah, Salt Lake City, Utah, United States

**(2015) Comparison of the EQ-5D-5L cognition bolt-on and EQ-HWB cognition items: Results from EQ-DAPHNIE data in China and Japan**

Fatima Al Sayah, PhD, University of Alberta, Edmonton, Alberta, Canada

**(2017) Symptom burden after dialysis initiation and associations with hospitalizations**

Devin Peipert, PhD, University of Birmingham, Birmingham, Illinois, United Kingdom

**(2019) Administering in-trial interviews using an AI chatbot: results of a proof of principle experiment**

Bill Byrom, PhD, Signant Health, Nottingham, United Kingdom

**(2021) Psychometric Validation of the Weight and Emotions Scale (WES) in Adults with Obesity or with Overweight and Obesity-related Complications**

Chisom Kanu, RPh, PhD, Eli Lilly & Company, Indianapolis, Indiana, United States

**(2023) Psychometric properties of Dutch-Flemish PROMIS Sleep measures in Dutch childhood cancer patients receiving follow-up care**

Anne Westerweel, PhD, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands, Utrecht, Netherlands

**(2025) Impact of transfusion dependent alpha- and beta-thalassemia on adult patients' health-related quality of life and work productivity: A multi-region real-world survey**

Christina Chamberlain, Agios Pharmaceuticals, Cambridge, Massachusetts, United States

*ISOQOL 32nd Annual Conference | Final Program Oral /Poster Presentations*

*Presenting authors indicated. The full author listing is available on the conference mobile app under the specific session. Last updated on 6 October 2025. For the most updated version of the final program, reference the mobile app.*

**(2027) Capturing the Impact of Facioscapulohumeral Muscular Dystrophy (FSHD) on Health-related Quality of Life (HRQoL): a systematic review of the reliability and validity of existing self-report instruments using COSMIN**

Jill Carlton, PhD, University of Sheffield, Sheffield, United Kingdom

**(2031) Cognitive Assessment in Schizophrenia: A Landscape Review of Instruments and Core Domains**

Angela Stroupe, MA, Parexel, Boston, Massachusetts, United States

**(2033) Subgroup or principal stratum analysis? A comparison and guidance for use of the principal stratum framework for COA endpoints**

Konstantina Skaltsa, PhD, IQVIA, Barcelona, Spain

**(2035) Mapping Treatment-Induced Adverse Events against HRQoL Questionnaires in Non-Small Cell Lung Cancer: Evaluation of the EORTC QLQ-C30 and QLQ-LC29**

Lotte Van der Weijst, PhD, EORTC, Brussels, Belgium

**(2037) Physical functioning measures by PROs on MDASI-Lung and 6-minute walk test during first year after chemoradiation and immunotherapy for NSCLC.**

Shu-En Shen, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

**(2039) Impact of Diabetes on Patient-Reported Outcomes After Lung Resection: A Prospective Cohort Study**

Wei Dai, Sichuan Cancer Hospital and Institute, Chengdu, China

**(2041) Dynamic Screening Nutritional Risk Index on Treatment Tolerance and Hospitalization Costs in Cancer Patient: A 3-Year Longitudinal Cohort Study Title page**

Xing Wei, Department of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of the University of Electronic Science and Technology of China, Chengdu, China

**(2043) Meaningful changes in physical function and pain in patients with knee osteoarthritis**

Xiaodan Tang, PhD, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States

**(2045) Meaningful within-patient change of PROMIS-Physical Function in patients with cancer cachexia in the phase 2 ponegromab study**

Jarjeh Fang, Pfizer, New York, New York, United States

**(2047) Evaluation of digital readiness in pulmonary hypertension: a study on health technology implementation and professional insights**

Frances Varian, MBChB, MRCP(UK), University of Sheffield, Sheffield, United Kingdom

**(2049) Study on Perioperative Symptom Trajectories in HPV-Infected Patients Based on Patient-Reported Outcomes**

Dengfeng Chen, Chongqing Medical University, Chongqing, China

**(2051) Linguistic and cross-cultural validation of the BODY-Q modules included in the Obesity ICHOM Set for their use in the Spanish and Catalan population**

Yolanda Pardo, PhD, Universitat Autònoma de Barcelona, Hospital del Mar Research Institute, CIBER de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain

**(2053) Meaningful within-patient change assessment of the Quality of Life-Bronchiectasis Questionnaire Respiratory Symptom score (QOL-B RSS)**

John Fastenau, Insmmed Incorporated, Bridgewater, New Jersey, United States

Friday, 24 October

9:35 AM - 10:15 AM

Friday Poster Session 201

Regency AB

**(2055) Methodological considerations for developing an Investigator Global Assessment (IGA) for use in dermatological studies**

Sarah Bentley, Adelphi Values Ltd, United Kingdom

**(2057) Future of Linguistic Validation: Will Machine Translation replace or augment LingVal?**

Willie Muehlhausen, SAFIRA, Cloughjordan, Ireland

**(2059) GenAI in Action: A Study on the Efficacy of AI Comparative Review Output**

Nathalie Azuaje, Bachelor in Translation, Lionbridge Technologies, Montreal, Quebec, Canada

**(2061) Title: Searching Smarter: Using Linguistics to Improve Symptom Reporting for Children with Cancer**

Stacey Crane, PhD RN CPON, University of Texas Health Science Center at Houston, Houston, Texas, United States

Friday, 24 October

1:30 PM – 3:00 PM

Concurrent Oral Sessions

**Oral Session 201: Pancreatic Cancer**

Regency CD

Session Chair: Anne Marie Lunde Husebø, PhD, Norway

**1:35 PM - 1:51 PM (201.1) Patient-reported outcomes (PROs) in the pragmatic comparative effectiveness trial of surgical versus nonsurgical management for patients with malignant bowel obstruction (S1316)**

Amylou Dueck, PhD, Mayo Clinic, Scottsdale, Arizona, United States

**1:51 PM - 2:07 PM (201.2) Patient-Reported Health Status Predicts Survival in Pancreatic Cancer: A Prospective Multicenter Cohort Study**

Jingyu Zhang, PhD, Chongqing Medical University, Chongqing, China

**2:07 PM - 2:23 PM (201.3) Tai Chi Game Theory of Psychological Resilience in Pancreatic Cancer Patients: Based on Grounded Theory**

Wen Zhou, State Key Laboratory of Ultrasound in Medicine and Engineering, Chongqing Medical University, Chongqing, China

**2:23 PM - 2:39 PM (201.4) Pain Trajectory between Survival and Death Groups after Pancreatic Cancer Diagnosis: a Multicenter Longitudinal Cohort Study**

Wen Zhou, State Key Laboratory of Ultrasound in Medicine and Engineering, Chongqing Medical University, Chongqing, China

**2:39 PM - 2:55 PM (201.5) Investigating the Mediating Effects within the Causal Chain of "FUAS Treatment—Pain Symptom Trajectory—Quality of Life" in Advanced Pancreatic Cancer Patients**

Qiuling Shi, Chongqing medical university, Dr, Chongqing, China

**Oral Session 202: Methods: DIF, Response Shift & Missing Data**

Executive A

Session Chair: Lori McLeod, PhD, United States

**1:35 PM - 1:51 PM (202.2) Response Shift in Patient-Reported Outcome Assessment among Older People Living with HIV/AIDS**

Huayu Li, Department of Social Medicine of School of Public Health, and Department of Pharmacy of the First Affiliated Hospital, Zhejiang University School of Medicine, China

**1:51 PM - 2:07 PM (202.3) A tree-based graded response theory model to test for differential item functioning in patient-reported outcome measures**

Tolulope Sajobi, PhD, University of Calgary, Calgary, Alberta, Canada

**2:07 PM - 2:23 PM (202.4) Evaluation of demographic DIF in the PROMIS and EORTC cognitive function measures in a nationally representative US sample**

Miranda Kapfhammer, Medical College of Wisconsin, Milwaukee, Wisconsin, United States

**2:23 PM - 2:39 PM (202.5) Predictors of missing instruments in a postoperative lung cancer cohort**

Shizhu Li, Chongqing Medical University, China

**Oral Session 203: Decision Making in Diagnosis Treatment & Monitoring**

Executive B

Session Chair: Kathrin Fischer, PhD, Germany

**1:35 PM - 1:51 PM (203.1) Implementation of PROMIS Global Health as a Screener to Trigger Construct-Specific PROs in Clinical Care: a mixed methods study of patients' perspectives**

Brittany Lapin, PhD MPH, Cleveland Clinic, Cleveland, Ohio, United States

Friday, 24 October

1:30 PM – 3:00 PM

Concurrent Oral Sessions

**1:51 PM - 2:07 PM (203.2) Assessment of patient needs and treatment benefits - a scoping review on the Patient Benefit Index (PBI)**

Stefanos Boudouroglou-Walter, M.Sc., University Medical Center Hamburg-Eppendorf, Hamburg, Germany

**2:07 PM - 2:23 PM (203.3) Psychometric properties of CHOICES-22, a patient reported experience measure of shared decision-making in perinatal care**

Rachel Breman, PhD, MSN, MPH, RN, University of MD, Baltimore School of Nursing, Baltimore, Maryland, United States

**2:23 PM - 2:39 PM (203.4) Framework for patient-reported measurement of diagnostic excellence**

Vadim Dukhanin, MD, MHS, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States

**2:39 PM - 2:55 PM (203.5) Impact of demographics, information access, and patient involvement in treatment decision-making on quality of life in leukaemia: insights from a global survey.**

Sam Salek, PhD RPh FFPM/FRCP GFMD MCMS FRPS FESCP, University of Hertfordshire, Hatfield, United Kingdom

**Oral Session 204: Cancer Symptom Assessment & Monitoring**

Executive CD

Session Chair: Maria Edelen, PhD, United States

**1:35 PM - 1:51 PM (204.1) Enhancing quality of life through policy-driven integration of clinical pharmacists in cancer pain management: Evidence from the PharmaCAP Trial in Nepal**

Sunil Shrestha, BPharm, PharmD, PhD, Kathmandu Cancer Center, Bhaktapur, Nepal

**NEW INVESTIGATOR ORAL PRESENTATION AWARD FINALIST**

**1:51 PM - 2:07 PM (204.2) ePRO Vision's Latest PROM-AI apps to Accelerate PROM Clinical Implementations**

Xu Frank Wang, Master of Management, ePRO Vision (Beijing) Health Technology Co., Ltd., Beijing, China

**2:07 PM - 2:23 PM (204.3) Development of a patient-reported outcome measure of postoperative recovery for lung cancer: a modular conceptual framework**

Cheng Lei, Ph.D, Sichuan Cancer Hospital and Institute, Chengdu, China

**2:23 PM - 2:39 PM (204.4) Time in Severe Symptom State With Eribulin Versus Paclitaxel in Patients With Locally Recurrent or Metastatic Breast Cancer (ACCRU RU011201I)**

Gina Mazza, PhD, Mayo Clinic, Scottsdale, Arizona, United States

**2:39 PM - 2:55 PM (204.5) Identifying Longitudinal Trajectories of Quality of Life and Associated Risk and Protective Factors Among Cancer Patients**

Jiwon Kim, Postdoctoral Scholar, Northwestern University, Chicago, Illinois, United States

**Oral Session 205: Cancer: QOL Assessment**

Milwaukee

Session Chair: Helen Parsons, PhD MPH, United States

**1:35 PM - 1:51 PM (205.1) Evaluating the Association Between Insurance Type and Financial Toxicity in Patients with Cancer**

Ada Lu, Fred Hutchinson Cancer Center, Seattle, Washington, United States

**STUDENT ORAL PRESENTATION AWARD FINALIST**

*ISOQOL 32nd Annual Conference | Final Program Oral /Poster Presentations*

*Presenting authors indicated. The full author listing is available on the conference mobile app under the specific session. Last updated on 6 October 2025. For the most updated version of the final program, reference the mobile app.*

Friday, 24 October

1:30 PM – 3:00 PM

Concurrent Oral Sessions

**1:51 PM - 2:07 PM (205.2) Assessing the Understanding of 'Quality of Life' Amongst Global Oncology Patients**

Hayley Simpson-Finch, BA, IQVIA, Reading, United Kingdom

**2:07 PM - 2:23 PM (205.3) Needs and health-related quality of life domains relevant to people in Europe with advanced cancer in palliative care: A systematic review of qualitative research**

Clara Amat-fernandez, Hospital del Mar Research Institute, Barcelona, Spain

**2:23 PM - 2:39 PM (205.4) Quality of Life in Oncology: Psychometric properties of the EUonQoL-Kit static version**

Olatz Garin, Hospital del Mar Research Institute, Barcelona, Spain

**2:39 PM - 2:55 PM (205.5) Evaluating missing data imputation strategies for PRO-CTCAE composite average**

Allison Deal, MS, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

Friday, 24 October

3:05 PM - 3:45 PM

Friday Poster Session 202

Regency AB

**(2014) A Qualitative Study to Understand the Supportive Care Needs of Adolescents with X-Linked Hypophosphatemia during the Transition to Adulthood**

Angela Rylands, PhD, CPsychol, Kyowa Kirin Ltd, Marlow, United Kingdom

**(2018) Pre-testing items for a new pain-specific patient-reported outcome measure for pelvic floor surgery through patient and clinician feedback**

Rasa Ruseckaite, PhD, Monash University, Melbourne, Australia

**(2020) Development of a conceptual model for cognitive impairment in a rare blood disorder, Thrombotic thrombocytopenic purpura**

Theresa Coles, PhD, Duke University School of Medicine, Durham, North Carolina, United States

**(2022) Adaptation of the Pediatric Quality of Life Inventory 3.0 (PedsQL) Neuromuscular Module: Lessons from Kazakhstan**

Ainur Bekitayeva, PhD-student, al-Farabi Kazakh National University, Almaty, Kazakhstan

**(2024) Real-world use of Vitaccess Real™ platform to assess quality of life impact with long-term use of Mucinex® in stable chronic bronchitis**

Samuel Llewellyn, MD, Vitaccess, Charlotte, North Carolina, United Kingdom

**(2026) A comprehensive literature review of definitions and methods for assessing saturation of qualitative data**

Miranda Lauher-Charest, BA, ScM, IQVIA Quality Metric, INC., Providence, Rhode Island, United States

**(2028) Translation and linguistic validation of the GENDER-Q into French for use in Canada**

Trisia Bretkopf, MSc, Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada

**(2030) Validation of a two-item version of the Perceived Health Competence Scale**

Jacquelyn S. Pennings, Ph.D., Vanderbilt University Medical Center, Nashville, Tennessee, United States

**(2032) Assessing the content validity of the Familial Chylomicronemia Syndrome Symptoms and Impacts scale (FCS-SIS) in severe hypertriglyceridemia (sHTG)**

Asia Sikora Kessler, PhD, Ionis Pharmaceuticals, Carlsbad, California, United States

**(2034) Evaluating the impact of missing data on scale reliability: A simulation study of a 10-Item HRQOL COA with varying item properties**

Adrian Jewett, Humanity, Los Angeles, California, United States

**(2036) Developing a Dutch PROPr value set: study design and lessons learned**

Ellen Elsmann, PhD, Department of Child and Adolescent Psychiatry and Psychosocial Care, Amsterdam UMC, Emma Children's Hospital, Amsterdam, Netherlands

**(2038) How long is too long? Review of screenshots for electronic implementation of EORTC instruments**

Dagmara Kulis, MA, EORTC, Brussels, Belgium

**(2040) EORTC item Q168: the psychometric performance of a single-item indicator of side-effect burden for people with cancer**

Sandra Nolte, PhD, Person-Centred Research, Eastern Health Clinical School, Monash University, Melbourne, Australia

**(2042) Study protocol for electronic patient-reported outcomes in a decentralised phase IV crossover trial for pulmonary arterial hypertension**

Frances Varian, MBChB, MRCP(UK), University of Sheffield, Sheffield, United Kingdom

ISOQOL 32nd Annual Conference | Final Program Oral /Poster Presentations

Presenting authors indicated. The full author listing is available on the conference mobile app under the specific session. Last updated on 6 October 2025. For the most updated version of the final program, reference the mobile app.

**(2044) Using Item Response theory for validity evidence using the DASS-21 with a rural population in the highlands of Peru**

Fiorella Guerrero, PhD, Duke University, Durham, North Carolina, United States

**(2046) Results from a literature review on available methods for defining Meaningful Between-Group Difference (MBGD) to be applied to the Attention-Deficit/Hyperactivity Disorder (ADHD) Investigator Symptom Rating (AISRS) Scale**

Dorothee Oberdhan, PhD, Otsuka Pharmaceutical Companies, Alexandria, Virginia, United States

**(2048) Measuring Health-Related Quality of Life using the EQ-5D-5L in the Lebanese Adult Population**

Fatima Al Sayah, Alberta PROMs & EQ-5D Research & Support Unit (APERSU), School of Public Health, University of Alberta, Edmonton, Alberta, Canada

**(2050) Reliability, Longitudinal Measurement Invariance, and Responsiveness of PROMs in a Japanese Web-Based Cognitive Behavioral Healthcare Intervention for Premenstrual Syndrome: A Secondary Analysis of a Randomized Controlled Trial**

Yoshitake Takebayashi, PhD., Department Health Risk Communication, Fukushima Medical University School of Medicine, Fukushima, Japan

**(2052) Development and validation of a biliary tract cancer symptom scale for mortality prediction: A Longitudinal Cohort Study**

Jian Li, Chongqing Medical University, Chongqing, China

**(2054) Change over Time in PROMIS Global Health across Neurological Populations**

Brittany Lapin, PhD MPH, Cleveland Clinic, Cleveland, Ohio, United States

**(2056) Evaluating the Effectiveness of an Electronic Data Collection Platform to Improve Patient Response Rates in a Canadian Orthopaedic Arthroscopic Surgery Registry**

Sarah Harris, BSc Eng, Pan Am Clinic Foundation, Winnipeg, Manitoba, Canada

**(2058) The Future of Linguistic Validation is Now: Enhancing Reconciliation Process Compliance with GenAI**

Nathalie Azuaje, Bachelor in Translation, Lionbridge Technologies, Montreal, Quebec, Canada

**(2060) Patient activation is associated with positive attitudes toward pain medications**

Richard Skolasky, ScD, Johns Hopkins University, Baltimore, Maryland, United States

**(2062) Functional constipation RCT: MIC/MCID application bias**

Zhengkun Hou, Guangzhou University of Chinese Medicine, Guangzhou, China

**(2064) Financial Insecurity and Discrimination Are Associated with Patient-Reported Quality of Life in Patients with Lupus**

Heather Gold, PhD, NYU Langone Health, New York, New York, United States

**(2066) Traditional Chinese Medicine Injections for Pain Relief in Cancer Patients: A Secondary Analysis of a Randomized Clinical Trial**

Shizhu Li, Chongqing Medical University, Chongqing, China

Friday, 24 October

3:50 PM – 5:20 PM

Concurrent Oral Sessions

**Oral Session 206: Qualitative Methods**

Regency CD

Session Chair: Kelly McCarrier, PhD MPH, United States

**3:55 PM – 4:11 PM (206.1) Leveraging MAXQDA AI-Assist for Qualitative Workflows in Patient Experience Data**

Trena Paulus, Ph.D., East Tennessee State University, JOHNSON CITY, Tennessee, United States

**4:11 PM - 4:27 PM (206.2) Generative AI for qualitative analysis: speed at what cost?**

Anne Skalicky, MPH, Evidera, Seattle, Washington, United States

**4:27 PM - 4:43 PM (206.3) Sentiment analysis of children's open-text survey responses during the pandemic: Using PROMs to assess differences in affective states**

Michiel Luijten, PhD, Amsterdam UMC, Amsterdam, Netherlands

**4:43 PM - 4:59 PM (206.4) Patient perspectives and experiences related to interviewing methodology for clinical outcomes assessment research**

Jake Macey, MSc, Clarivate, Clinical Outcome Assessment, London, United Kingdom

**4:59 PM – 5:15 PM (206.5) How low can you go? PROM developers' perspectives on the involvement of young children in concept elicitation and cognitive interviews in quality of life research**

Jill Carlton, University of Sheffield, PhD, Sheffield, United Kingdom

**Oral Session 207: Pediatrics**

Executive A

Session Chair: Christina Zigler, PhD MSEd, United States

**3:55 PM – 4:11 PM (207.1) Psychometric properties of Dutch-Flemish PROMIS Pediatric measures in the Dutch pediatric oncology population 8-17 years**

Anne Westerweel, PhD, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands, Utrecht, Netherlands

**4:11 PM - 4:27 PM (207.2) Health-related quality-of-life among pediatric sibling hematopoietic stem cell donors; findings from RDSafe and DonorKids QL studies**

Galen Switzer, PhD, University of Pittsburgh, Pittsburgh, Pennsylvania, United States

**4:27 PM - 4:43 PM (207.3) PROtocols matter: A systematised evaluation of adherence to Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) patient-reported outcome guidelines in interventional paediatric oncology trials.**

Denise Connolly, MB BCh BAO, MCnrcSc, The Hospital for Sick Children, Toronto, Ontario, Canada

**4:43 PM - 4:59 PM (207.4) Development and Validation of the Observer-Reported Outcome for Children with Cancer (ObsRO-CC)**

Hua-Yu Li, Department of Social Medicine, School of Public Health, Zhejiang University School of Medicine, Hangzhou, China

**4:59 PM – 5:15 PM (207.5) Family members/partners of people with autism experience a major impact on quality of life as measured by the Family-Reported Outcome Measure (FROM-16)**

Sam Salek, School of Life & Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom

**Oral Session 208: Translation & Cultural Adaptation**

Executive B

Session Chair: Emily Parks-Vernizzi, MBA, United States

**3:55 PM – 4:11 PM (208.1) Cross-cultural validation of the Dermatology Life Quality Index (DLQI) across 13 European languages**

Sam Salek, RPh, PhD, University of Hertfordshire, Hatfield, United Kingdom

*ISOQOL 32nd Annual Conference | Final Program Oral /Poster Presentations*

*Presenting authors indicated. The full author listing is available on the conference mobile app under the specific session. Last updated on 6 October 2025. For the most updated version of the final program, reference the mobile app.*

Friday, 24 October

3:50 PM – 5:20 PM

Concurrent Oral Sessions

**4:11 PM - 4:27 PM (208.2) Refining the Spanish version of the awareness and beliefs about cancer (ABC) instrument: Supporting valid assessment for cancer knowledge and screening interventions**

Christopher M. Amissah, PhD, MPhil, University of Maryland School of Pharmacy, Baltimore, Maryland, United States

**4:27 PM - 4:43 PM (208.3) Data and Methods to Support Translation of Critical COA Terminology in a Shifting Linguistic Validation Landscape: Improving Quality of Life in the AI-mediated Age**

Tim Poepsel, MS, PhD, RWS, St. Louis, Missouri, United States

**4:43 PM – 4:59 PM (208.5) Assessing the Quality of AI-Generated Swahili Translations of the BREAST-Q: Enhancing PROM Accessibility in Low-Resource Settings**

Oluchukwu Dele-Oni, BS, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, United States

**Oral Session 209: Cancer: Breast & Ovarian**

**Executive CD**

Session Chair: David Cella, PhD, United States

**3:55 PM – 4:11 PM (209.1) A systematic review of Patient-Reported Outcome Measures (PROMs) to assess Health-Related Quality of Life (HRQoL) for breast cancer patients on adjuvant endocrine therapy: Application of the COSMIN guidelines**

Rila Su, DrPH, M.D, PhD, Inner Mongolia People's Hospital, Hohhot, China

**4:11 PM - 4:27 PM (209.2) Health-Related Quality of Life (HRQoL) Assessment using the Validated Mongolian FACT-ES among Mongolian Women with Breast Cancer (BC) on Adjuvant Endocrine Therapy (AET)**

Rila Su, DrPH, M.D, PhD, Inner Mongolia People's Hospital, Hohhot, China

**4:27 PM - 4:43 PM (209.3) Recovery from Breast Cancer Surgery: Implementation of the ICHOM Standard Order to Understand the Patient Perspective**

Eva Roy, MD, Brigham and Women's Hospital, Boston, Massachusetts, United States

**4:43 PM - 4:59 PM (209.4) Assessing Socioeconomic Disparities in Patient-Reported Outcome Measure Response Rates Among Ovarian Cancer Surgery Patients**

Jason B. Liu, MD, MS, MD Anderson Cancer Center, Houston Texas, United States

**4:59 PM – 5:15 PM (209.5) How does Surgical Complexity impact Health-Related Quality of Life in Patients with Ovarian Cancer?**

Jason B. Liu, MD, MS, MD Anderson Cancer Center, Houston Texas, United States

**Oral Session 210: PROMs in Registries & Care**

**Milwaukee**

Session Chair: Deborah Mattila, United States

**3:55 PM – 4:11 PM (210.1) Implementation of patient-reported outcome measures in clinical registries worldwide**

Rasa Ruseckaite, PhD, Monash University, Melbourne, Victoria, Australia

**4:11 PM - 4:27 PM (210.2) Individual and Community-Level Social Determinants Associated with Representation in a Cellular Therapy Registry**

Carlos Litovich, MPH, Medical College of Wisconsin, Milwaukee, Wisconsin, United States

**4:27 PM - 4:43 PM (210.3) Barriers and facilitators to Patient Reported Outcome (PRO) collection. Interim findings from a mixed-methods, multi-site study**

Devin Peipert, PhD, University of Birmingham, Birmingham, United Kingdom

*ISOQOL 32nd Annual Conference | Final Program Oral /Poster Presentations*

*Presenting authors indicated. The full author listing is available on the conference mobile app under the specific session. Last updated on 6 October 2025. For the most updated version of the final program, reference the mobile app.*

Friday, 24 October

3:50 PM – 5:20 PM

Concurrent Oral Sessions

**4:43 PM - 4:59 PM (210.4) How do we ensure ePRO solutions meet accessibility standards?**

Florence Mowlem, BSc, MSc, PhD, uMotif, London, United Kingdom

**4:59 PM – 5:15 PM (210.5) Evaluation of enrollment rates to PRO data collection in a large clinical registry in the US – the first 5 years**

Idayat Akinola, MBBS, MPH, Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Saturday, 25 October

9:20 AM - 10:00 AM

Saturday Poster Session 301

Regency AB

**(3015) Evaluating agreement metrics used in analytical validation: A simulation study for a digital measure of step count**

Aleksandra Sjöström-Bujacz, PhD, Patient-Centered Solutions, IQVIA, Stockholm, Sweden

**(3017) Predictors in infancy of disease-specific quality of life in adolescents born with esophageal atresia - a nationwide prospective observational study in Sweden**

Michaela Dellenmark-Blom, PhD, Associate Professor, Department of Pediatric Surgery, Queen Silvia Children's Hospital, Sahlgrenska University Hospital, Gothenburg, Sweden, Institute of Clinical Sciences, Department of Pediatrics, Queen Silvia Children's Hospital, Gothenburg, Sweden

**(3019) Psychometric Validation of the Eating Behavior and Appetite Questionnaire (EBAQ) in Adults with Obesity or with Overweight and Obesity-related Complications**

Chisom Kanu, RPh, PhD, Eli Lilly & Company, Indianapolis, Indiana, United States

**(3021) Quality of life in the rural highlands of Peru**

Fiorella Guerrero, PhD, Duke University, Durham, North Carolina, United States

**(3023) Understanding the natural history of cognitive impairment in people living with immune thrombotic thrombocytopenic purpura: qualitative perspectives of patients and their observers**

Laura Mkumba, MS, Duke University, Durham, North Carolina, United States

**(3025) Using the EORTC Item Library to assess patient-reported symptomatic adverse events: Development of the EORTC-PRO-AE inventory**

Claire Piccinin, Quality of Life Department, EORTC, Brussels, Belgium

**(3027) Smart Pediatric Oncology Tracker of Symptoms (SPOTS): Design and Development of a Web-Based Interface for the Pediatric PRO-CTCAE**

Stacey Crane, PhD RN CPON, University of Texas Health Science Center at Houston, Houston, Texas, United States

**(3029) Pre-Treatment Readiness Tool for Sarcoma**

Mariam Husain, MD, MPH, Ohio State University James Comprehensive Cancer Center, Columbus, Ohio, United States

**(3031) Test-retest reliability and concurrent validity of performance outcome measures in sarcopenia**

Xiaodan Tang, PhD, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States

**(3033) Equivalence of Paper-Based and Smartphone-Based Patient-Reported Outcomes Using the Perioperative Symptom Assessment of Lung Surgery (PSA-Lung): A Randomized Crossover Equivalence Study**

Xing Wei, Department of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of the University of Electronic Science and Technology of China, Chendu, China

**(3035) Validation and reliability of a Patient-Reported Outcome Tool for Assessing Anxiety in patients with HPV infection**

Wenlin Wu, Chongqing Medical University, Chongqing, China

**(3037) A Virtual Focus Group Model for Qualitative Cognitive Debriefing of Patient-Reported Outcome Measures**

Sara Shaunfield, PhD, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States

*ISOQOL 32nd Annual Conference | Final Program Oral /Poster Presentations*

*Presenting authors indicated. The full author listing is available on the conference mobile app under the specific session. Last updated on 6 October 2025. For the most updated version of the final program, reference the mobile app.*

Saturday, 25 October

9:20 AM - 10:00 AM

Saturday Poster Session 301

Regency AB

**(3039) Evaluating Construct Validity of the Patient-Reported Outcomes Measurement Information System 16-Item Profile in Total Laryngectomy Patients**

Maria Edelen, PhD, RAND Corporation, Boston, Massachusetts, United States

**(3041) PRO-CTCAE Composite Average Validation in Prostate Cancer Phase 3 Trial**

Minji Lee, PhD, Mayo Clinic, Rochester, Minnesota, United States

**(3045) Religious beliefs and health outcomes: results from a population-based study in Japan**

Yosuke Yamamoto, Department of Healthcare Epidemiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

**(3047) Assessing comprehensibility of Dutch patient-reported outcome measures (PROMs) for people with low literacy skills**

Ellen Elsmann, Amsterdam UMC, location University of Amsterdam, Epidemiology and Data Science, Amsterdam, The Netherlands, Amsterdam, Netherlands

**(3049) Development of a Modular Quality of Life Assessment Tool for Breast Cancer Patients Based on Patient-Reported Outcomes (PROs)**

Xu Wei, Chongqing Medical University, Chongqing, China

**(3051) Did The Kids Understand? Translating Key Concepts in Norwegian PROMIS Pediatric and Proxy Measures**

Abigail Boucher, FACITtrans, Chicago, Illinois, United States

**(3053) Cross-cultural adaptation of the EQ-TIPS into Chichewa (Malawi): preliminary findings**

Lucky Gift Ngwira, PhD, Health Economics and Policy Unit, Kamuzu University of Health Sciences, Blantyre, Malawi

**(3055) Bivariate latent change score modeling of pain and physical function in osteoarthritis**

Aaron Kaat, PhD, Northwestern University, Chicago, Illinois, United States

**(3057) Using a meaningful change item to support interpretations of meaningful score differences derived using traditional anchors**

Alyssa Bamer, MPH, Clinical Outcomes Solutions, Tucson, Arizona, United States

**(3059) Statistical vs. Clinical Significance: Shifting the Focus to Clinical Relevance in Patient - Reported Outcome Measures of Functional Dyspepsia**

Zhengkun Hou, Guangzhou University of Chinese Medicine, Guangzhou, China

**(3061) The impact of psychological wellness and caregiver quality of life on patient quality of life after CAR T cell therapy**

Emma DuMez, BA, Medical College of Wisconsin, Milwaukee, Wisconsin, United States

**(3063) Simulation of screen-to-CAT algorithm for PROMIS anxiety and depression in solid organ transplant recipients**

Jad Fadlallah, MEng, HBSc, University Health Network, Toronto, Ontario, Canada

**(3065) Social communication assessment priorities of adults with traumatic brain injury and speech-language pathologists**

Lindsey Byom, PhD, Viterbo University, LaCrosse, Wisconsin, United States

**(3067) Using multiple graphical approaches to support estimation of meaningful within patient change (MWPC) and meaningful score regions (MSRs)**

Helen Doll, Clinical Outcomes Solutions, Folkestone, United Kingdom

*ISOQOL 32nd Annual Conference | Final Program Oral /Poster Presentations*

*Presenting authors indicated. The full author listing is available on the conference mobile app under the specific session. Last updated on 6 October 2025. For the most updated version of the final program, reference the mobile app.*

Saturday, 25 October

9:20 AM - 10:00 AM

Saturday Poster Session 301

Regency AB

**(3069) Reliability and validity of the Colombian version of Kidscreen-10 in school children and adolescents**

Martha Rodriguez, MSc, Universidad Santo Tomás, Bucaramanga, Colombia

Saturday, 25 October

4:00 PM - 5:30 PM

Concurrent Oral Sessions

**Oral Session 301: Meaningful Change Methodology**

**Regency CD**

Session Chair: Jessica Roydhouse, PhD, Australia

**4:05 PM - 4:21 PM (301.1) What anchor correlation value should I use when deriving Meaningful Within Patient Change (MWPC) values**

Kim Cocks, PhD, Adelphi Values, Manchester, United Kingdom

**4:21 PM - 4:37 PM (301.2) Establishing Meaningful Change Thresholds Through Personalized Narratives and Tailored Definitions: A Feasibility Study in Patients with Cancer**

Kathleen Yost, PhD, Mayo Clinic, Rochester, Minnesota, United States

**4:37 PM - 4:53 PM (301.3) A Comparison of Minimally Important Difference Definitions for Quality of Life in Four Clinical Trials**

Salene Jones, PhD, Fred Hutchinson Cancer Center, Seattle, Washington, United States

**4:53 PM – 5:09 PM (301.4) Which of these response choices would reflect a meaningful change? Methods of asking about meaningful change in qualitative interviews outside of a clinical trial**

Sonya Eremenco, MA, Critical Path Institute, Patient-Reported Outcome Consortium, Tucson, Arizona, United States

**5:09 PM - 5:25 PM (301.5) The impact of severity prevalence on cut points estimated from receiver operating characteristic (ROC) curve analysis; implications for threshold and meaningful change estimation**

Helen Doll, MSc DPhil, Clinical Outcomes Solutions, Folkestone, United Kingdom

**Oral Session 302: Application of AI in PRO Research**

**Executive A**

Session Chair: Katie Kunze, PhD, United States

**4:05 PM - 4:21 PM (302.1) Predicting oncologic adverse events from patient-reported symptoms: AI models developed using data from a large national multicenter trial.**

Chris Gibbons, Oracle Health, Austin, Texas, United States

**4:21 PM - 4:37 PM (302.2) Assessment of Treatment Response Through the Use of Personalized Endpoints: Using Artificial Intelligence to Assist Goal Attainment Scaling**

Gunes Sevinc, Ardea Outcomes, Halifax, Nova Scotia, Canada

**4:37 PM – 4:53 PM (302.5) Patient perceptions toward the use of AI in clinical and research settings**

Richard Skolasky, ScD, Johns Hopkins University, Baltimore, Maryland, United States

**Oral Session 303: Neurology**

**Executive B**

Session Chair: TBD

**4:05 PM - 4:21 PM (303.1) Understanding the experience of people living with amyotrophic lateral sclerosis: a qualitative study and conceptual model informed by patients, caregivers, and clinicians**

William (Ben) Nowell, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States

**4:21 PM - 4:37 PM (303.2) The trajectory of depression-related symptom clusters following stroke**

Qi Zhang, Associate professor, Sun Yat-Sen University, Guangzhou, China

**4:37 PM - 4:53 PM (303.3) Major impact of Multiple Sclerosis on family members and partners: evidence using the Family Reported Outcome Measure (FROM-16)**

Sam Salek, School of Life & Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom

Saturday, 25 October

4:00 PM - 5:30 PM

Concurrent Oral Sessions

**4:53 PM – 5:09 PM (303.4) Developing a conceptual framework of health-related quality of life of informal carers in Amyotrophic Lateral Sclerosis (ALS)**

Jill Carlton, PhD, University of Sheffield, Sheffield, United Kingdom

**5:09 PM - 5:25 PM (303.5) Minimally important differences (MIDs) and minimally important changes (MICs) were determined for the Vestibular Schwannoma Quality of Life (VSQOL) Index**

Kathleen Yost, PhD, Mayo Clinic, Rochester, Minnesota, United States

**Oral Session 304: Electronic Symptoms Surveillance**

Executive CD

Session Chair: Rachel Cusatis, PhD, United States

**4:05 PM - 4:21 PM (304.1) Establishing optimal Cut-off Points for Remote Monitoring of Cancer Symptoms via ePROs in China's Primary Health Care Settings**

Dai Wei, Sichuan Clinical Research Center for Cancer, Chengdu, China

**4:21 PM - 4:37 PM (304.2) Defining Critical Symptom Profiles to Build ePRO-based Pathway for Patient Care During First Year After Chemoradiation and Immunotherapy for NSCLC**

Shu-en Shen, MS, MD Anderson Cancer Center, Houston, Texas, United States

**4:37 PM - 4:53 PM (304.3) ePRO-MAI-CRC: AI-Powered Real-Time Symptom Monitoring and Proactive Triage for Home-Based Chemotherapy in Colorectal Cancer**

Wei Xu, PhD, College of Public Health, Chongqing Medical University, Chongqing, China

**4:53 PM – 5:09 PM (304.4) Dynamic Electronic Monitoring of Chemotherapy-Induced Neurotoxicity: Patterns and Clinical Impact in colorectal and breast Tumor Cohorts**

Wei Xu, PhD, College of Public Health, Chongqing Medical University, Chongqing, China

**5:09 PM - 5:25 PM (304.5) Understanding response rates of electronic PROMs in clinical care: trends and characteristics**

Anouk Groenewegen, MSc, Department of Child and Adolescent Psychiatry and Psychosocial Care, Amsterdam UMC, University of Amsterdam, Emma Children's Hospital, Amsterdam, Netherlands

**Oral Session 305: Health Valuation & Utility Assessment**

Milwaukee

Session Chair: Andria Joseph, United Kingdom

**4:05 PM - 4:21 PM (305.1) Collaborative involvement in valuing health-related quality of life is underdeveloped: Novel insights and emerging recommendations**

Philip Powell, PhD, University of Sheffield, Sheffield, United Kingdom

**4:21 PM - 4:37 PM (305.2) Have relative preferences for different dimensions of health changed over time? Evidence from the UK using EQ-5D**

Donna Rowen, PhD, Sheffield Centre for Health and Related Research, University of Sheffield, Sheffield, United Kingdom

**4:37 PM - 4:53 PM (305.3) Assessing Health State Utilities Across Different Severity Levels of Friedreich Ataxia by the General Population**

Kristen Deger, Evidera (Part of Thermo Fisher Scientific), Bethesda, Maryland, United States

**4:53 PM – 5:09 PM (305.4) Are child patient reported-outcome measures used to inform assessments of health technologies and highly specialised technologies? A review of recent evidence in England**

Donna Rowen, PhD, Sheffield Centre for Health and Related Research, University of Sheffield, Sheffield, United Kingdom

Saturday, 25 October

4:00 PM - 5:30 PM

Concurrent Oral Sessions

**5:09 PM - 5:25 PM (305.5) Impact of Severe Neonatal Complications on Long-Term Health-Related Quality of Life in Very Preterm and/or Very Low Birth Weight Survivors: Evidence from Meta-Analysis.**

Corneliu Bolbocean, University of Oxford, Oxford, Arkansas, United Kingdom

**(1) Association of Particulate Matter 2.5 Exposure and Health-related Quality of Life among 38,724 Patients in Massachusetts, United States**

Chengbo Zeng, Ph.D., Brigham and Women's Hospital, Boston, Massachusetts, United States

**(2) Arabic Translation and Adaptation of the CVID\_QoL Questionnaire to Measure Health-Related Quality of Life of Adults with Common Variable Immune Deficiency**

Salim Zridi, PhD Candidate, Laboratory of Clinical Immunology, Inflammation and Allergy (LICIA), Faculty of Medicine and Pharmacy, Hassan II University, Casablanca, Morocco, Benslimane, Morocco

**(3) Physical, mental and social functioning of children in pediatric physical therapy: mental health matters**

Dorinde L. Korteling, Amsterdam UMC location University of Amsterdam, Emma Children's Hospital, Child and Adolescent Psychiatry & Psychosocial Care, Meibergdreef 9, Amsterdam, The Netherlands

**(4) Child-caregiver agreement and test-retest reliability of nine PROMIS item banks in pediatric physical therapy**

Dorinde L. Korteling, Amsterdam UMC location University of Amsterdam, Emma Children's Hospital, Child and Adolescent Psychiatry & Psychosocial Care, Meibergdreef 9, Amsterdam, The Netherlands

**(5) Responsiveness of pediatric v2.0 and v3.0 PROMIS Pain Interference, Upper Extremity and Mobility**

Dorinde L. Korteling, Amsterdam UMC location University of Amsterdam, Emma Children's Hospital, Child and Adolescent Psychiatry & Psychosocial Care, Meibergdreef 9, Amsterdam, The Netherlands

**(6) Bridging the gap: Understanding child and caregiver discrepancies in patient-reported outcome measures**

Aline Thorkelsson, Department of Psychology, University of Alberta, Undergraduate student, Edmonton, Alberta, Canada

**(7) : Using an argument-based approach to validation to evaluate three PROMs for intensive outpatient child and adolescent mental health services**

Erin McCabe, MScPT, PhD, Department of Physical Therapy, University of Alberta, Edmonton, Alberta, Canada

**(8) Key informant experiences with patient-reported outcome measures in child and adolescent mental health**

Erin McCabe, MScPT, PhD, Department of Physical Therapy, University of Alberta, Edmonton, Alberta, Canada

**(9) Psychometric evaluation of the PROMIS SD SF 8b and ISI in women experiencing sleep disturbances associated with menopause: reliability, validity, and responsiveness**

Andrew Trigg, Bayer Plc, Reading, United Kingdom

**(10) Symptom prevalences and changes among gastrointestinal cancer patients receiving chemotherapy**

Chengbo Zeng, Ph.D., Brigham and Women's Hospital, Boston, Massachusetts, United States

**(11) Bridging Technology and Trust: Leveraging AI and Health Behavior Theory to Combat Misinformation in African American Communities**

Akorfa Adobor, MCW, Milwaukee, Wisconsin, United States

**(12) How AI Can Help Sickle Cell Disease Management in African American Communities**

Akorfa Adobor, MCW, Milwaukee, Wisconsin, United States

**(13) Estimating Meaningful Score Differences and Meaningful Score Regions for the PROMIS® Pediatric Asthma Impact Scale**

Jing Yuan, PhD, Duke University, Durham, North Carolina, United States

**(14) Patient preference information for HTA: A rapid review of HTA community perspectives**

Takako Kaneyasu, Kinugasa Research Organization, Ritsumeikan University, Kyoto, Japan

**(15) Exploring health-related quality of life and patient perceptions in persons with above-knee bone-anchored prostheses: a mixed methods study**

Mayank Rehani, MSc, Division of Physical Medicine & Rehabilitation, Department of Medicine, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada

**(16) A reconceptualization of Maslow: A chronic illness-informed framework for health-related quality of life**

Angel Sheu, B.S., Anne Burnett Marion School of Medicine at Texas Christian University, Fort Worth, Texas, United States

**(17) How, for Whom, under What Circumstances, and Why is Mental Healthcare for Anxiety Supposed to Improve Well-being for People Receiving Dialysis?**

Lori Suet Hang Lo, MSc, BScN, Faculty of Nursing, University of Alberta, Edmonton, Alberta, Canada

**(18) Identifying and explaining variation in emotional well-being measurement bias**

Richard Sawatzky, PhD, RN, Trinity Western University, Langley, British Columbia, Canada

**(19) Quality-of-life discounting: A behavioral economics framework for understanding the underutilization of preventive health interventions**

Angel Sheu, B.S., Anne Burnett Marion School of Medicine at Texas Christian University, Fort Worth, Texas, United States

**(20) Beyond the individual: Bronfenbrenner's ecological systems theory as a proxy for understanding pediatric health-related quality of life**

Angel Sheu, B.S., Anne Burnett Marion School of Medicine at Texas Christian University, Fort Worth, Texas, United States

**(21) Mapping the Evidence for Outcomes in Telehealth Across Four Domains: A Scoping Review**

Fatemeh Ehteshami, PhD student, university of western ontario, London, Ontario, Canada

**(22) To what extent do older adults differ in how they respond to questions about their physical and mental health?**

Ava Mehdipour, PhD, Trinity Western University, Langley, British Columbia, Canada

**(23) Improving communication in primary care using a mixed-methods approach to creating data-driven personas**

Jeanette Jackson, Health Quality Council of Alberta, Calgary, Alberta, Canada

**(24) The Association Between Self-stigma of Mental Illness and Quality of Life of Adults Living with Depression: A Systematic Review.**

Refah Alqahtani, University of Dundee, Dundee, United Kingdom

**(25) Assessing security in telemedical care from the patient's perspective: Further development of the SeCu questionnaire**

Klara Greffin, Dr., University of Greifswald, Greifswald, Germany

**(26) Challenges in analysing the effect of treatment on PROs in cancer registry data**

Emma Martin, MSc, AdelphiValues PCO, Macclesfield, United Kingdom

**(27) Key Domains Affected by Lower Limb Amputation: Patient and Healthcare Professional Perspectives**

Justin-Pierre Lorange, M.D., Universite de Montreal, Montreal, Quebec, Canada

**(28) Grounded in Lived Experience: Community Voices Refine the Obesity-Specific Preference-Based Weight-Related Quality of Life (PB-WRQL) Prototype**

Ana Moga, PT, MSc, PhD candidate, Faculty of Medicine, School of Physical Therapy, Rehabilitation Science, McGill University, Montreal, Quebec, Canada

**(29) Evaluating the PB-WRQL Prototype Against Generic Preference-Based HRQL Measures in People Living with Obesity**

Ana Moga, PT, MSc, PhD candidate, Faculty of Medicine, School of Physical Therapy, Rehabilitation Science, McGill University, Montreal, Quebec, Canada

**(30) Measurement properties of PROMIS 29 v2.1 in German, French and Italian for Swiss population in a cross-sectional study**

Thanh Elsener, Institute of Biomedical Ethics and History of Medicine, University of Zurich, Zurich, Switzerland

**(32) A Mixed Methods Analysis Using Trial Data to Describe Patients with Glycogen Storage Disease Type Ia Who Met Baseline Expectations for Meaningful Change in Daily Cornstarch Intake**

Diane M. Turner-Bowker, PhD, Ultragenyx Pharmaceutical, Novato, California, United States

**(33) Evaluating Responsive Shift in Total Knee Arthroplasty Patients**

Ademola Itiola, B.Pharm, MPH, MSc, School of Public Health, University of Alberta, Edmonton, Alberta, Canada

**(34) Child and family-important outcomes in pediatric randomized controlled trials over a 10-year period**

Nora Fayed, PhD, MScOT, Queen's University, Kingston, Ontario, Canada

**(1023) Promoting professional well-being through resilience and self-care: A qualitative study**

Sabrina Figueiredo, PhD, The George Washington University, Washington, District Of Columbia, United States

**(1072) Development and Content Validation of a Survey Instrument to Assess Physician Attitudes Toward Real-World Evidence in U.S. Cancer Care Using Modified COSMIN Methodology**

Sabrina Figueiredo, PhD, Mac, George Washington University School of Medicine and Health Sciences, Washington, District Of Columbia, United States